Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting.

Communications biology - 9 Jun 2020

Landgraf Kyle E, Williams Steven R, Steiger Daniel, Gebhart Dana, Lok Stephen, Martin David W, Roybal Kole T, Kim Kaman Chan

Abstract excerpt

We have developed a chimeric antigen receptor (CAR) platform that functions as a modular system to address limitations of traditional CAR therapies. An inert form of the human NKG2D extracellular domain (iNKG2D) was engineered as the ectodomain of the CAR to generate convertibleCARTM-T cells. These cells were specifically directed to kill antigen-expressing target cells only in the presence of an activating...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigen Presentation
Share to Immunotherapy, Adoptive

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interleukin-2

Share to Lymphoma, B-Cell

Share to Mice, Inbred NOD

Share to Mice, SCID

Share to NK Cell Lectin-Like Receptor Subfamily K

Share to Receptors, Chimeric Antigen

Source

Open in PubMed Open full text

Identifiers

PMID: 32518350
DOI: 10.1038/s42003-020-1021-2
PMCID: PMC7283332

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting.PMID 32518350Read ↗

Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapySemantic proximity Read ↗

Recent Progress in NKG2D CAR-NK Cells for Cancer ImmunotherapySemantic proximity Read ↗

T Cell Activation Machinery: Form and Function in Natural and Engineered Immune ReceptorsSemantic proximity Read ↗

Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagersSemantic proximity Read ↗

Synthetic Hybrid Receptors for Safer and Programmable T Cell TherapySemantic proximity Read ↗

Solid tumor immunotherapy using NKG2D-based adaptor CAR T cellsSemantic proximity Read ↗

Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.Semantic proximity Read ↗

Unlocking the potential of Tregs: innovations in CAR technologySemantic proximity Read ↗

Engineering NKG2D ligand affinity transforms EGFR-targeted NK cell engagers into high-potency effectors against pancreatic cancerSemantic proximity Read ↗

CAR-NK cells with dual targeting of PD-L1 and MICA/B in human lung cancer H1299 cell tumor modelSemantic proximity Read ↗

NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful DevelopmentSemantic proximity Read ↗

P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.